business
Maryland Board Sets $274 Monthly Cap on Ozempic for State Purchases
The Maryland Prescription Drug Affordability Board voted to cap the price of Ozempic at $274 per 30-day supply for state and local government purchases starting January 2027. The limit is expected to save $5.8 million annually and follows a similar action taken by the board in recent weeks.
May 18, 6:08 PM·1m read1 source
foxbusiness.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for the Ozempic diabetes treatment. The board will oversee a process to lower the cost of the type 2 diabetes medicine for state and local governments by January 2027. At that time the price will be capped at $274 for a 30-day supply. 8 million a year.
The expected cost was benchmarked against the maximum fair price paid by Medicare, said Andrew York, executive director of the Maryland board. The board is expected to begin acting in 2028 to set upper payment limits on high-cost drugs purchased by all Marylanders in the commercial insurance market as well. Nine states have been pursuing the idea of prescription drug affordability boards.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
